MetVital is a clinical-stage, metabolic therapy company developing first-in-class, broadly applicable methods to improve cellular metabolism to ameliorate disease. MetVital is currently studying its lead product candidate, Anhydrous Enol-Oxaloacetate (AEO) in a Phase 1 clinical trial for Amyotrophic Lateral Sclerosis (ALS), and has FDA approval for commercial investigation of Glioblastoma Multiforme (GBM, brain cancer) in a Phase 2 clinical trial. A Phase 2A investigation into Alzheimer's Disease was recently completed and supports further development. MetVital's lead candidate has been designated by the FDA as "Orphan Drugs" for the treatment of GBM and gliomas, ALS and Hepatocellular Carcinoma (Liver Cancer).
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Anhydrous Enol-Oxaloacetate (AEO)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):